Rezubio Pharmaceuticals (宁康瑞珠) has filed the IND application for novel small-molecule gut-restricted GPR40 agonist RZ-629 in China. Rezubio Pharmaceuticals Co., Ltd is a biotech company founded by Yusheng Xiong and Hong-Ping Guan in Zhuhai, China. Rezubio RZ-629 According to the ACS Meeting Spring 2024 , RZ-629 is a novel gut-restricted membrane-anchored drug GPR40 agonist discovered by Rezubio. RZ-629 showed outstanding efficacy in both glucose and body weight reductions, with shallow blood exposure. The gut-restricted compound design effectively avoided liver and potential pancreas toxicities as nearly 100% of the parent drug was excreted in feces, with bile and urine accounting for less than 0.01% of the dose. In 2020 and 2022, Rezubio filed patents (WO2023134712/WO2022028317) covering GPR40 agonists, which can be used for treating various disorders, conditions, or diseases such as Type 2 diabetes. In some examples, compounds covalently linked to the hydrophilic group T A have a s
China Biotech XYZ Shares Updates Related to New Drug Development in China